PRESS RELEASES

Date Title and Summary View
Toggle Summary GlycoMimetics Completes Enrollment of Relapsed/Refractory AML Patient Cohort in Phase 2 Portion of Clinical Trial of GMI-1271
Clinical trial now fully enrolled with 91 patients: 25 in newly diagnosed arm and 66 in relapsed refractory arm Interim data to be presented at ASCO and EHA Meetings showing high remission rates with acceptable tolerability Patients with higher levels of novel biomarker were more likely to achieve
View HTML
Toggle Summary GlycoMimetics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics , Inc. (NASDAQ: GLYC) today announced the closing of its underwritten public offering of 8,050,000 shares of its common stock at a public offering price of $11.50 per share, which includes the exercise in full by the underwriters of their option to
View HTML
Toggle Summary GlycoMimetics' GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the European Commission , based on a favorable recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products , has granted orphan designation for the company's drug candidate
View HTML
Toggle Summary GlycoMimetics Announces Pricing of Public Offering of Common Stock
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a price to
View HTML
Toggle Summary GlycoMimetics Announces Proposed Public Offering of Common Stock
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it intends to offer and sell, subject to market conditions, 6,000,000 shares of its common stock
View HTML
Toggle Summary GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML
Company to provide update and host conference call today on clinical data to be presented at 2017 ASCO and EHA Meetings ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the release of abstracts containing new data from the ongoing Phase 2 clinical trial of its
View HTML
Toggle Summary GlycoMimetics' GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for treatment of adult relapsed/refractory acute myeloid leukemia (AML) to the company's drug candidate GMI-1271, an
View HTML
Toggle Summary GlycoMimetics Reports Program Updates and First Quarter 2017 Results
Completed enrollment in the first of two patient cohorts in the Phase 1/2 acute myeloid leukemia (AML) trial of GMI-1271 Presented preclinical data for GMI-1271 and GMI-1359 in multiple myeloma at AACR Annual Meeting 2017 Company management will host a conference call on Thursday, May 18,
View HTML
Toggle Summary GlycoMimetics Announces Publication of Preclinical Data Showing Role of E-selectin Ligands in Multiple Myeloma
Research demonstrates that E-selectin ligand in myeloma confers more aggressive disease and greater resistance to bortezomib (standard of care) GMI-1271 was able to restore sensitivity to bortezomib ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc.
View HTML
Toggle Summary GlycoMimetics to Present New AML Clinical Data at ASCO 2017 Annual Meeting
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the company will provide an update on clinical data from its Phase 1 and 2 studies of GMI-1271 at the 2017 American Society for Clinical Oncology in Chicago . GMI-1271 is an antagonist of E-selectin, for
View HTML